To demonstrate treatment efficacy in Crohn’s disease (CD), regulatory authorities require that trials include an endoscopic remission endpoint. However, standardized endoscopic assessment of mucosal improvement, such as the simple endoscopic score of CD (SES-CD), is not typically recorded by clinicians in practice or outside of clinical trials. A previous study demonstrated the Simplified Endoscopic Mucosal Assessment of CD (SEMA-CD) correlates strongly with SES-CD and that SEMA-CD is a score that can be easily used by clinicians in routine practice (Adler et al., 2021).